injectievloeistof
Sponsors
Leiden University Medical Center, Celgene Corp., Algemeen ziekenhuis Rivierenland, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Conditions
Menière's diseaseMultiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Newly Diagnosed Transplant Ineligible Multiple Myeloma PatientsPatients scheduled for shoulder operationsRelapsed or Refractory Multiple Myeloma (RRMM)Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
Phase 1
Phase 3
A multicenter, double-blinded, randomized, placebo-controlled trial to compare the effectiveness of intratympanic injections methylPREDnisolone versus placebo in the treatment of vertigo attacks in MENière’s disease (PREDMEN trial).
RecruitingCTIS2023-503340-13-00
Start: 2023-10-05Target: 148Updated: 2024-11-18
Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial.
WithdrawnCTIS2023-506062-31-00
Target: 260Updated: 2023-08-16
Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial.
RecruitingCTIS2023-506062-31-01
Start: 2024-01-02Target: 260Updated: 2023-11-09
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma
(RRMM) (KarMMa-3)
Active, not recruitingCTIS2023-509848-10-00
Start: 2019-06-12Target: 138Updated: 2025-11-28
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib And Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): Successor-1
RecruitingCTIS2023-509859-13-00
Start: 2022-11-09Target: 322Updated: 2025-09-25
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
RecruitingCTIS2024-519827-16-00
Start: 2025-09-30Target: 713Updated: 2025-11-25